LVgp120duoCAR

**LVgp120duoCAR** is a lentiviral vector (LV) encoding a bispecific duoCAR architecture for engineering autologous T cells into **LVgp120duoCAR-T cells**, an investigational cell therapy targeting HIV-infected cells. It expresses two distinct chimeric antigen receptors (CARs): one with the mD1.22 domain (engineered CD4 D1 variant) binding the conserved CD4-binding site on HIV-1 gp120, and the other with the m36.4 heavy chain-only antibody domain targeting a CD4-induced (CD4i) epitope near the co-receptor binding site on gp120, linked to 4-1BB costimulatory and CD3ζ signaling domains for enhanced persistence and activation. Developed using HIV-1 lentiviral vectors for efficient T cell transduction, it enables sequential gp120 engagement, potent cytotoxicity (>99% in vitro HIV suppression), cytokine release (IFN-γ, IL-2), and resistance to diverse HIV-1 strains; primary indication is HIV infection management via reservoir reduction, tested in a phase I/IIa dose-escalation trial (NCT04648046) with cyclophosphamide conditioning options and analytic treatment interruption.